Key result
Adding AI-ECG to HFA-ICOS score boosts CTRCD prediction to a C-statistic of ~0.91.
Why the study?
Current HFA-ICOS risk score for baseline stratification in patients receiving BRAF/MEK inhibitors relies on traditional variables and may miss subclinical myocardial vulnerabilities that AI-ECG could detect.
Does AI-ECG improve the prediction of cancer therapy-related cardiac dysfunction in melanoma patients receiving BRAF/MEK inhibitors compared to clinical risk scores alone?
Cohort (n=61)
Does AI-ECG improve the prediction of cancer therapy-related cardiac dysfunction in melanoma patients receiving BRAF/MEK inhibitors compared to clinical risk scores alone?
Answers are grounded in this paper and cite their sources.
AI-ECG is a promising, low-cost tool that may enhance baseline clinical risk stratification for predicting severe cardiotoxicity in patients receiving targeted cancer therapies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zeidaabadi et al. (2026) conducted a cohort in Melanoma treated with BRAF/MEK inhibitors (n=61). AI-ECG combined with HFA-ICOS score vs. HFA-ICOS score alone was evaluated on Prediction of Moderate/Severe CTRCD (Grade ≥ 2) at 6 months (C-statistic 0.905, 95% CI 0.783-0.963, p=0.030). Adding AI-ECG to the HFA-ICOS clinical score improved the prediction of moderate/severe cancer therapy-related cardiac dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: